APPLIED GENETIC TECHNOLOGIES CORP AGTC Cash Flow

Applied genetic technologies corp (AGTC)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13
Operating activities:
Net income (loss)
-41,903	-19,225	-14,783	-2,006	1,896	-17,694	-18,703	-21,300	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	6,333	9,501	10,767	-1,381	-12,070	-20,365	-28,060	-24,318	-20,878	-18,140	-14,225	-15,908	0	0	0
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Share-based compensation expense
3,282	3,253	3,658	4,029	4,241	4,668	4,905	5,193	5,517	5,494	5,655	5,606	5,563	5,430	5,304	5,007	4,305	4,081	3,536	2,820	2,745	1,942	1,198	825	0	0	0
Share-based collaboration expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	636	0	0	0	-	-	-	-	-	-	-	-
Depreciation and amortization
1,235	1,283	1,274	1,273	1,311	1,270	1,262	1,175	1,076	1,022	945	912	849	805	671	567	472	388	384	376	371	357	344	334	0	0	0
Recovery of bad debts
-	-	-	-358	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment discount accretion
518	715	821	790	667	411	139	-85	-256	-329	-284	-402	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash lease expense
-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest on lease liabilities
-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Equity in net losses of an affiliate
-33	-32	-37	-35	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value adjustments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	441	0	0	0
Changes in operating assets and liabilities:
Grants receivable
-	-	-	-186	4	24	37	36	-36	125	148	-780	-842	-818	-1,384	-409	0	0	0	-	-	-	-	343	0	0	0
Prepaid and other assets
-673	-1,633	-1,140	-1,635	-345	-135	1,172	1,903	1,461	2,543	730	240	1,229	130	-4,758	1,562	1,189	1,413	5,718	-261	-1,004	-358	971	1,351	0	0	0
Deferred revenues
-	-	-	-28,392	-30,588	-13,000	-11,742	-18,529	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
1,425	49	-1,691	327	128	628	561	-53	505	319	1,386	-333	-668	-100	-6,529	140	707	286	6,538	228	-490	-316	-51	156	0	0	0
Operating lease liabilities
0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase (decrease) in deferred revenues
-	-	-	-	-	-	-	-	-	-	-	-38,230	-42,160	-45,977	-46,898	63,664	0	0	0	-	-	-	-	-212	0	0	0
Accrued and other liabilities
2,789	3,011	1,728	604	776	1,149	1,618	2,326	-126	-1,081	-1,022	-352	1,585	948	132	3,063	3,040	3,915	4,135	1,866	2,107	1,395	1,913	1,226	0	0	0
Net cash used in operating activities
-35,391	-33,517	-34,755	-23,457	-22,663	-22,996	-23,286	-32,520	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investing activities:
Net cash (used in) operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-28,406	-28,041	-29,763	70,991	71,981	74,874	79,515	-19,485	-15,966	-14,606	-14,012	-11,928	0	0	0
Purchases of property and equipment
894	516	366	163	89	609	573	662	833	310	848	739	0	0	0	-	-	-	-	225	294	284	201	158	0	0	0
Purchases of and capitalized costs related to intangible assets
349	337	243	148	0	0	0	-	-	-	-	152	148	128	115	121	135	126	123	98	173	188	173	218	0	0	0
Maturities of investments
86,000	88,000	86,883	94,119	84,336	89,231	98,829	100,900	110,606	97,263	94,693	103,244	159,365	153,893	132,296	109,968	44,373	52,973	85,659	121,079	0	0	0	-	-	-	-
Maturity of short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Purchases of investments
43,843	59,667	61,933	74,781	0	0	0	-	-	-	-	67,542	110,478	124,771	184,508	208,180	160,025	146,922	90,778	102,864	146,508	136,020	114,108	79,950	0	0	0
Net cash provided by investing activities
36,914	27,480	24,341	19,027	-3,211	-23,192	1,288	33,015	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing activities:
Proceeds from the issuance of common stock, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19,211	19,211	19,211	19,181	32,009	0	0	0	-	-	-	-
Proceeds from exercises of common stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	45,947	26,066	-54,819	-100,804	-118,026	-94,226	-5,420	17,892	-31,345	-34,042	-41,532	-50,826	0	0	0
Proceeds from exercise of common stock options
-	0	0	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes paid related to equity awards
0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments made toward finance lease liability
-	0	50	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of convertible preferred stock warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of bank term notes and capital lease
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash (used in) provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	75	72	302	19,494	19,446	19,525	19,329	32,157	0	0	0	-	-	-	-
Net cash provided by (used in) financing activities
35,398	135	214	68	-189	-179	-264	-136	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
36,921	-5,902	-10,200	-4,362	-26,063	-46,367	-22,262	359	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental information:
Net increase(decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	1,838	17,616	-1,903	-84,280	-10,319	-26,599	173	93,424	30,564	36,453	35,231	38,979	-270	0	0	0
Cash paid during the year for income taxes
-	-	-	-	-	-	-	617	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost related to purchase of intellectual property included in accrued and other liabilities
-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares issued for no consideration
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-